Activate Now
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Repair Damaged Mitochondria and Reduce Fatigue Up to 45%

How One LLND Treats Lyme disease and Co-infections Using Natural Medicine

'Healthy' foods differ by individual

Surprising Benefits of Cinnamon

Specific vitamin D levels linked to heart problems

A Sleep Intervention For Children With Autism: A Pilot Study

Higher vitamin D levels may be protective against acute rhinosinusitis

Basic Vitamin A Primer

Curcumin: The All In One Solution

Saffron reduces oxidative stress in metabolic syndrome patients

Print Page
Email Article

XMRV-Positive Patient Responses to Ampligen® – 40-Week Trial Reported Sep 8 at XMRV Workshop

  [ 14 votes ]   [ Discuss This Article ] • September 22, 2010

Retrovirus antibody positive CFS patients show response to Ampligen®, an experimental therapeutic, relative to XMRV negative group.

Hemispherx Biopharma, Inc. [presented] new clinical data(1) on the possible inter-relationships of XMRV positivity/chronic fatigue syndrome/Ampligen® responsiveness at the 1st International Workshop on XMRV held at the National Institutes of Health in Bethesda, MD, on September 7 and 8, 2010.

CFS is a severe disorder consisting of profound fatigue and a variety of other debilitating symptoms that affects up to 4 million Americans. Recently, DNA was identified from a human gamma retrovirus (XMRV) in 67% of CFS subjects. Evidence also suggested that approximately 50% of the CFS subjects mounted a specific antibody response against XMRV (Science 326, 585-589 (2009)).

The objective of this study was to compare demographic parameters and health/performance status of XMRV antibody positive vs. negative CFS subjects enrolled in a Phase III clinical trial evaluating the safety and efficacy of a toll-like receptor 3 agonist, rintatolimod (PolyI:PolyC12U, Ampligen). The response to Ampligen with regard to the primary endpoint, treadmill exercise tolerance testing (ETT), in this population was also evaluated.

Two hundred-eight (208) evaluable subjects, who met the original (1988) and revised (1994) Centers for Disease Control criteria for CFS, participated in this randomized, placebo-controlled, double-blinded, multicenter study.

Only severely debilitated patients with a Karnofsky Performance Scale between 40-60 were selected for this study.

The primary endpoint was exercise treadmill duration. Subjects received Ampligen (200-400 mg) or an equivalent volume of placebo (saline) twice weekly by intravenous infusion for 40 weeks.

Baseline (or earliest available specimen) serum samples from all 208 subjects were analyzed for antibodies directed against XMRV.

The XMRV antibody positive cohort [33.7% of the 208 subjects, according to the report abstract] had a greater relative percentage of subjects showing a greater than 25% increase in ETT with Ampligen treatment compared to placebo than the XMRV antibody negative cohort.

• The results also suggest that the XMRV antibody negative subjects with CFS [66.3% of the 208] have a lower activity level and a reduced ability to complete normal daily activities at baseline.

If validated as a relevant basis for targeting the XMRV positive CFS patient sub-population the observed response advantage of the XMRV may translate into needing a smaller sample size for future research using a placebo-controlled parallel design to obtain 80% power (Alpha=0.05): 216 XMRV antibody positive subjects vs. 330 XMRV antibody negative subjects.

Additional studies to further evaluate XMRV in this CFS population are currently underway….
1. See Abstract P_14, “Comparison of demographic parameters and health/performance status of XMRV antibody positive vs. negative CFS subjects in a phase III trial.” Reviews in Antiviral Therapy & Infectious Diseases, Vol 8; 2010, page 30. By Strayer D, Stouch B, Mikovits J, Carter W. Hemispherx Biopharma, Philadalphia, PA; Whittemore Peterson Institute, Reno, NV, USA.

Sources: Excerpts from Hemispherx Biopharma ( press release, Wed, Sep 8, 2010; presentation abstract cited above.

Note: Because Ampligen’s maker is a publicly traded entity, its caveat statement regarding any press release includes warnings that any press release statements other than historical information should be considered ‘forward-looking’ and “represent the company’s judgment as of the date of the release.” They “do not imply that any study product will ever be approved commercially for the studied or other treatment indications."

Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Ultra EPA  - Fish Oil Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Subscribe Now!
Receive up-to-date ME/CFS, Fibromyalgia & Lyme Disease treatment and research news
 Privacy Guaranteed  |  View Archives

Repair Damaged Mitochondria and Reduce Fatigue Up to 45%

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?
Breaking Through the Mental Fog Breaking Through the Mental Fog
Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You
Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!
Clinically Studied Joint Relief Product for FM & ME/CFS Clinically Studied Joint Relief Product for FM & ME/CFS

What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Causes
Fibromyalgia Treatments
Fibromyalgia Diet
Fibromyalgia Medications
M.E. & CFS
What is M.E./CFS?
M.E./CFS Diagnosis
M.E./CFS Symptoms
M.E./CFS Causes
M.E./CFS Treatments
M.E./CFS Diet
M.E./CFS Medications
What is Lyme Disease?
Lyme Disease Diagnosis
Lyme Disease Symptoms
Lyme Disease Causes
Lyme Disease Treatments
Lyme Disease Diet
Lyme Disease Medications
M.E. & CFS
Lyme Disease
General Health
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing